Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
Luciano J. Costa(University of Alabama at Birmingham), Parameswaran Hari(Medical College of Wisconsin), Carolyn C. Jackson(Centro de Investigación del Cáncer), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Kelly Godby(University of Alabama at Birmingham), Mark A. Fiala(Washington University in St. Louis), Ravi Vij(Washington University in St. Louis), Shaji Kumar(Mayo Clinic), Ankit Kansagra(Southwestern Medical Center), Sundar Jagannath(Mount Sinai Hospital), Saurabh Chhabra(Medical College of Wisconsin), Amarendra Kumar Neppalli(Medical University of South Carolina), Yubin Kang(Duke University), Natalie S. Callander(University of Wisconsin–Madison), Satish Valluri(Janssen (United States)), Robert F. Cornell(Dana-Farber Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Arnob Banerjee(Johnson & Johnson (United States)), Thomas G. Martin(University of California San Francisco Medical Center), Ehsan Malek(Roswell Park Comprehensive Cancer Center), Michaela Liedtke(Cancer Institute (WIA)), Jordan M. Schecter(Centro de Investigación del Cáncer), Yi Lin, Hong Tian(Massey University), Jennifer Marino(Janssen (United States))
Cited by 45
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k